What this trial studies
This double-blind, placebo-controlled, randomised pilot trial aims to assess the effect of oral soy isoflavone consumption on skin ageing parameters in post-menopausal women.
Conditions in scope
- Skin Ageing
Interventions
- soy isoflavones (Dietary Supplement) — 1 capsule daily for 84 days
- Placebo (Dietary Supplement) — 1 capsule daily for 84 days
Who can join
Women only · Ages 40 Years to 65 Years · Accepts healthy volunteers.
Inclusion criteria
- Healthy subject.
- Sex: female.
- Age: from 40 to 65 years (inclusive).
- Phototype: I to IV on the Fitzpatrick scale.
- Post-menopausal subject, with last menstrual period at least 12 months prior to screening and who is not using hormonal contraception.
- Subject having Crow's feet wrinkles from grade 2 to 5 on Bazin's scale.
- Subject having under eyes wrinkles.
- Subject agreeing not to change her alimentary and cosmetic habits during the study.
Exclusion criteria
- Women with childbearing potential or women on long term hormonal contraception whose childbearing potential is difficult to ascertain.
- Subject deprived of her freedom by administrative or legal decision.
- Subject under guardianship or unable to provide consent.
- Subject in a social or healthcare institution.
- Subject suspected to be non-compliant according to the investigator's judgment.
- Subject participating in any other clinical study or being in an exclusion period for a previous study.
- Subject having crow's feet wrinkles with grades \< 2 or \> 5 on Bazin's scale.
- Subject with a tattoo, a scar, moles, too many hairs or anything on the studied zones which might interfere with the evaluation.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Villeurbanne | Eurofins Dermscan Pharmascan | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2023-10-27
- Primary completion: 2024-02-26
- Last update posted: 2025-04-10
- First posted: 2023-09-21
Sponsor & contact
Lead sponsor: The Archer-Daniels-Midland Company (Industry)
Collaborators: Eurofins Dermscan Pharmascan
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Change in Crow's Feet wrinkles (Ra) (day 0, day 84)
Cutaneous relief parameters (Ra - Average roughness) on Crow's Feet wrinkles measured with fringe projection acquisitions
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06047145 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.